# Comparison of broad-spectrum anti-Pseudomonal beta-lactam antibiotics versus targeted therapy for neutropenic patients with methicillin-susceptible Staphylococcus aureus bloodstream infections

## TL;DR

This study compares two antibiotic treatments for bloodstream infections in neutropenic patients and finds similar outcomes.

## Contribution

It provides evidence on the safety of targeted therapy for MSSA infections in neutropenic patients.

## Key findings

- No significant difference in clinical outcomes between broad-spectrum and targeted therapy.
- MSSA-targeted beta-lactam therapy is safe for neutropenic patients with MSSA bloodstream infections.

## Abstract

The safety of the utilization of methicillin-susceptible Staphylococcus aureus (MSSA)-targeted therapy for the treatment of MSSA bloodstream infections in the setting of neutropenia is not well studied. This single-center, retrospective cohort study of 40 patients found no significant difference in clinical outcomes between broad-spectrum anti-Pseudomonal and MSSA-targeted beta-lactam therapy.